XP Chemistries (XPC) Q4 2024 earnings summary

Executive summary

• Achieved strategic milestones in 2024, advancing regulatory approval for capsaicin in animal feed and strengthening financial position through successful capital raises.

• Focused on preparing for commercial launch in 2025, including securing production capacity and distribution channels.

• XP Chemistries leverages patented technology to produce sustainable, high-purity capsaicin from forest raw materials, targeting multiple market segments.

Financial highlights

• Net sales for 2024 were 284 TSEK, down from 664 TSEK year-over-year; Q4 net sales were 55 TSEK, down from 92 TSEK.

• Operating loss for 2024 was -8,928 TSEK, improved from -10,106 TSEK; Q4 operating loss was -2,290 TSEK, nearly flat year-over-year.

• Result before tax for 2024 was -8,835 TSEK, compared to -9,976 TSEK in 2023.

• Cash and cash equivalents at year-end 2024 were 2,145 TSEK, down from 7,827 TSEK at the end of 2023.

• Equity at year-end 2024 was 21,565 TSEK, compared to 25,688 TSEK at year-end 2023.

Outlook and guidance

• Anticipates regulatory approval for capsaicin in animal feed by May 2025, with commercial launch preparations underway.

• Expects increased demand for sustainable feed ingredients and plans to expand into new market segments.